Fig. 1From: Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort studyFlow-chart of inclusion and exclusion criteria for the eligibility of patients with a diagnosis of asthma and receiving at least one prescription of Dupilumab during the period December, 1st 2020 and July, 31st 2021. ¥Patients (i) with an active exemption, or (ii) who experienced a previous hospital admission with diagnosis for asthma or asthma-related respiratory problemsBack to article page